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Abstract: Four new dammarane-type triterpenoid saponins, namely notoginsenosides SFt1–SFt4 (1–4) were isolated from the 
steamed leaves of Panax notoginseng (Burk.) F. H. Chen (Araliaceae), together with 17 known saponins. Their structures were 
established on the basis of detailed spectroscopic analyses and acidic hydrolysis. The known ginsenosides Rk2 and Rh3 were  
obtained from P. notoginseng for the first time. All of these new saponins showed no in vitro cytotoxicity against five human cancer 
cell lines (HL-60, SMMC-7712, A-549, MCF-7, and SW480). 
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Introduction 
Panax notoginseng (Burk.) F. H. Chen (Araliaceae), a  
famous traditional Chinese medicinal (TCM) herb, is mainly 
cultivated in Yunnan and Guangxi province of China. Both 
roots and leaves have been used medicinally by the local  
people of its growing area for a long time.1 Traditionally, the 
roots have been used in both raw and processed forms. The 
raw one has been mainly used for injuries from falls and  
removing blood stasis, while the processed one has been used 
as a tonic to promote blood circulation.2 The leaves had the 
similar effects on hematological and cardiovascular systems as 
the roots. Dammarane-type triterpenoid saponins are known to 
be the main bioactive constituents in P. notoginseng. So far, 
more than 70 saponins have been isolated from different  
organs of this herbs.3 Our previous study on the steamed roots 
of P. notoginseng resulted in the identification of five new and 
23 known dammarane-type saponins, part of which are the 
minor constituents in non-processed roots.4 As part of our con-
tinuing search for new saponins from Panax plants, a  
detailed chemical investigation on the steamed leaves of P. 
notoginseng was carried out, which led to the isolation of four 
new dammarane-type triterpenoid saponins (1–4), along with 
17 known ones. Their structures were established based on the 
detailed spectroscopic analyses and acidic hydrolysis. The new 
saponins 1–4 were tested for their cytotoxic activities against 
five human cancer cell lines (HL-60, SMMC-7712, A-549, 







































































































G: ginsenoside, NG: notoginsenoside
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Results and Discussion 
After defatted by petroleum ether, the ethanolic extract of 
steamed leaves of P. notoginseng was subjected to column 
chromatography repeatedly over Diaion 101 resin, silica gel, 
MCI gel CHP 20P, RP-8, and RP-18, and preparative-HPLC 
to afford four new dammarane-type triterpenoid saponins, 
namely, notoginsenosides SFt1–SFt4 (1–4), together with 17 
known compounds. 
The known compounds were identified as ginsenoside R10,5 
ginsenosides Rk2,6 Rh3,6 Rk1,6 Rg5,6 Rs57 and Rs4,7 20(R/S)-
ginsenosides Rh2,8 Rg39 and Rs3,10 20(R/S)-notoginsenoside 
Ft1,11 ginsenosides F2,8 Rb3,8 Rc 8 and Fc,12 gypenoside IX,8 
and 20(R/S)-protopanaxtriol,13 respectively, by comparison the 
spectroscopic and physical data with those previously reported 
values. 
Compound 1 was a white amorphous powder. The molecular
formula C36H62O9 was deduced from the HRESIMS data (m/z 
673.4067, [M + Cl]−). The 1H and 13C NMR spectroscopic data 
indicated the presence of a protopanaxdiol aglycone [δC 26.8 
(CH2, C-2), 88.8 (CH, C-3) and 18.5 (CH2, C-6)]13 and a  
hexosyl unit [δH 4.96 (1H, d, J = 7.8 Hz), δH 107.0 and 63.1]]. 
Acidic hydrolysis of 1 gave D-glucose as the sole sugar moiety,
which was determined to have a β configuration on the basis 
of the large coupling constants of the anomeric proton [δH 4.96 
(1H, d, J = 7.8 Hz)]. The aforementioned data demonstrated 
that compound 1 should be a protopanaxdiol triterpenoid sap-
onin. Compared with protopanaxdiol,14 the aglycone of 1 pos-
sesses a terminal double bonds [δH 5.26, 4.91 (each 1H, s), δH 
109.9 (CH2) and 150.0 (quaternary carbon)] and an oxygenat-
edmethine, instead of a methyl (C-27) and a methylene (C-24) 
in protopanaxdiol. The structure of 1 was further deduced by 
HMBC and HSQC experiments. The HMBC correlations 
(Figure 1) of δH 2.09 (m, CH2) with δC 73.1 (C-20), δH 4.41 (m, 
oxygenated CH) and 1.88 (s, CH3) with δC 109.9 and 150.0 
(terminal double bond), the glucosyl H-1' (δH 4.96) with C-3 
(δC 88.8) of aglycone were observed. The configuration of the 
C-24 was established to be R by the comparison of the 13C 
NMR data with those of the C-24 epimers of ginsenoside-
Table 1. 1H NMR data (500 MHz, C5D5N) of compounds 1–4 (δ in ppm, J in Hz). 
No. 1 2  3 a 4a 
1 1.50 m; 0.74 br. s 1.48 m; 0.75 br. s 1.78 m; 0.75 m 1.74 m; 0.74 m 
2 1.90 m; 1.47 m 2.20 m; 2.08 m 2.18 br. d (11.6); 1.80 m 2.18 dd (13.5, 3.0); 1.78 m 
3 3.37 dd (11.5, 4.0) 3.38 dd (11.5, 3.5) 3.29 dd (12.0, 4.0) 3.28 dd (12.0, 4.4) 
5 0.72 t (11.5) 0.73 t (11.5) 0.68 t (11.2) 0.67 t (11.2) 
6 1.52 m; 1.40 m 1.48 m; 1.34 m 1.40 m 1.47 m; 1.04 m 
7 1.48 m; 1.20 br. d (11.5) 1.43 m; 1.22 br. d (11.0) 1.46 m; 1.38 m 1.42 m; 1.20 br. d (10.5) 
9 1.42 m 1.40 m 1.38 m 1.39 m 
11 2.17 m; 1.39 m 2.00 m; 1.37 m 2.05 m 1.97 m; 1.35 m 
12 4.25 m 4.25 m 3.87 m 3.91 m 
13 2.12 m 2.06 m 3.68 m 3.68 m 
15 2.02 m; 1.52 m 1.56 m; 1.02 m 1.48 m; 1.10 m 1.50 m; 1.04 m 
16 2.22 m; 1.81 m 2.20 m; 2.08 m 2.05 m; 1.56 br. s 1.97 m; 1.48 m 
17 2.37 m 2.37 m 2.79 m 2.77 m 
18 0.95 s 0.94 s 0.95 s 0.94 s 
19 0.78 s 0.79 s 0.78s 0.78 s 
21 1.44 s 1.46 s 5.14 s 1.81 s 
22 2.04 m; 1.54 m 1.90 m; 1.83 m 2.46 m; 2.29 m 5.49 t (6.8) 
23 2.09 m 2.53 m; 1.80 m 2.96 m; 2.37 m 2.77 m 
24 4.41 m 3.82 d (10.0) 5.28 m 5.21 t (7.2) 
26 1.88 s 1.54 s 1.64 s 1.60 s 
27 5.26 s; 4.91 s 1.51 s 1.58 s 1.56 s 
28 1.31 s 1.32 s 1.28 s 1.27 s 
29 0.98 s 1.00 s 1.10 s 1.09 s 
30 0.95 s 0.96 s 0.99 s 0.99 s 
1' 4.96 d (7.8) 4.97 d (7.7) 4.94 d (7.6) 4.93 d (7.7) 
2' 4.02 m 4.06 t (8.5) 4.09 m 4.08 m 
3' 4.01 m 4.25 m 4.37 m 4.36 m 
4' 3.93 m 3.90 m 4.13 m 4.22 m 
5' 4.25 m 4.03 m 4.28 m 4.24 m 
6' 4.60 dd (11.5, 5.0); 4.41 m 4.61 br. d (11.5); 4.42 dd (11.5, 5.0) 4.58 br. d (11.6); 3.97 m 4.57 br. d (10.0); 4.34 m 
1'' 5.53 d (7.6) 5.52 d (7.7) 
2'' 4.23 m 4.20 m 
3'' 4.34 m 4.27 m 
4'' 4.13 m 4.11 m 
5'' 4.29 m 4.35 m 
6'' 4.48 dd (11.0, 1.8); 4.27 m 4.47 dd (11.2, 2.4); 4.26 m 
1''' 5.42 d (6.5) 5.41 d (6.5) 
2''' 4.09 m 4.12 m 
3''' 4.36 m 4.32 m 
4''' 4.13 m 4.14 m 
5''' 3.97 m 3.85 m 
aRecorded at 400 MHz. 
 
Figure 1.  The key HMBC correlations (H→C) of compound 1. 
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Rg715 and majoroside-F2.16 The lower-field shifted 13C NMR 
data of C-24 (δC 76.1) and C-26 (δC 109.9) [majoroside-F2: δC 
75.8 (C-24S), 109.3 (C-26); ginsenoside-Rg7: δC 76.2 (C-24R)), 
110.2 (C-26)] clearly confirmed the configuration of the C-24 
hydroxyl group in 1. Accordingly, the structure of 1 was elu-
cidated and named as notoginsenoside SFt1. 
Compound 2, a white amorphous powder, had a molecular 
formula C36H64O10 on the basis of the HRESIMS (m/z 
691.4150, [M + Cl]−). The 1H and 13C NMR spectroscopic data 
resembled that of 1, except for the loss of the double bond and 
the appearance of an additional oxygen-bearing quaternary 
carbon signal at δC 72.8. In the HMBC spectrum, the correla-
tions of δH 1.54, 1.51 (each 3H, s, Me-26 and Me-27) and 3.82 
(1H, d, J = 10.0 Hz, oxygenated CH) with δC 72.8 (C-25), and δH 3.82 (1H, d, J = 10.0 Hz, oxygenated CH) with δC 33.9 (C-
23) and 27.0 (C-22) were observed, which confirmed that the 
additional hydroxyl group should be linking to C-25. The  
configuration of the C-24 (C-24: δC 80.1) was indicated to be 
24R on the comparison with the chemical shift values of  
cyclocantogenin [δC 76.99 (C-24S)]17 and tarecilioside A [δC 
80.5 (C-24R)].18 Hence, the structure of compound 2 was  
established and named notoginsenoside SFt2. 
Compound 3 had the molecular formula C47H78O16 based on 
the HRESI data (m/z 897.5215, [M − H]−). The 1H and 13C 
NMR data revealed that 3 was similar to the known  
dammarane saponin, ginsenoside Rk1,6 except for an additional 
pentosyl unit. Acidic hydrolysis of 3 gave D-glucose and D-
xylose as sugar residues. The large coupling constants of the 
anomeric protons (J = 7.6, 7.6, 6.5 Hz) indicated the β config-
urations of two glucosyl and one xylosyl moieties. Locations 
of the sugar moieties were established by the HMBC correla-
tions of the inner glucosyl H-1' (δH 4.94), the middle glucosyl 
H-1'' (δC 5.53), and the xylosyl H-1''' (δH 5.42) with C-3 (δC 
88.9), the inner glucosyl C-2' (δC 83.0) and the middle glucosyl
C-2'' (δC 84.6), respectively. Accordingly, the structure of 
compound 3 was established and named as notoginsenoside 
SFt3. 
The molecular formula of compound 4 was deduced as 
C47H78O16 by the HRESIMS (m/z 897.5235, [M − H]−). The 1H 
and 13C NMR features of 4 were closely related to those of 3, 
including the same trisaccharide moiety. The only difference 
was that the terminal double bonds between C-20 and C-21 in 
3 were changed to be a middle double bond between C-20 and 
C-22 in 4. This could be determined by comparison of the 13C 
NMR data with those of the known compound ginsenoside Rg5 
and further confirmed by HMBC correlations of δH 1.81 (Me, 
C-21) with δC 51.0 (C-17), 140.2 (C-20) and 123.6 (C-22). 
Therefore, the structure of compound 5 was deduced and 
named as notoginsenoside SFt4. 
Compounds 1–4 were tested for their cytotoxic activity 
against five human cancer cell lines, HL-60 myeloid leukemia, 
SMMC-7721 hepatocellular carcinoma, A-549 lung cancer, 
MCF-7 breast cancer, and SW480 colon cancer, applying the 
MTT method. However, none of them exhibited cytotoxicity 
at a concentration of 40 μM. 
The present study indicated that the chemical constituents of 
the steamed leaves of P. notoginseng were significantly  
different from the un-processed ones.8 After steamed, a mass 
of low-pole triterpenoid saponins came forth. Being similar 
with the roots, the processed and the air-dried leaves must 
have different pharmacological activities and quality standard. 
 
Experimental Section 
General Experimental Procedures. Optical rotations were 
performed on a P-1020 polarimeter (JASCO, Tokyo, Japan). 
IR spectra were measured on a Bruker Tensor 27 spectrometer 
with KBr pellets. 1D and 2D NMR spectra were run on Bruker 
AM-400 and DRX-500 instruments operating at 400 and 500 
MHz for 1H, and 100 and 125 MHz for 13C, respectively. 
Coupling constants are expressed in Hertz and chemical shifts 
Table 2. 13C NMR data (125 MHz, C5D5N) of compounds 1–4 (δ in ppm). 
No. 1 2 3a 4a No. 1 2 3a 4a 
1 39.2 (CH2) 39.7 (CH2) 39.8 (CH2) 39.3 (CH2) 25 150.0 (C) 72.8 (C) 131.2 (C) 131.3 (C) 
2 26.8 (CH2) 26.8 (CH2) 26.8 (CH2) 28.8 (CH2) 26 18.5 (CH3) 26.2 (CH3) 25.8 (CH3) 25.8 (CH3) 
3 88.8 (CH) 88.8 (CH) 88.9 (CH) 88.9 (CH) 27 109.9 (CH2) 26.0 (CH3) 17.8 (CH3) 17.8 (CH3) 
4 39.7 (C) 39.2 (C) 39.3 (C) 40.3 (C) 28 28.2 (CH3) 28.2 (CH3) 28.1 (CH3) 28.1 (CH3) 
5 56.4 (CH) 56.4 (CH) 56.4 (CH) 56.4 (CH) 29 15.9 (CH3) 15.8 (CH3) 16.7 (CH3) 15.8 (CH3) 
6 18.5 (CH2) 18.5 (CH2) 18.5 (CH2) 18.5 (CH2) 30 17.1 (CH3) 17.1 (CH3) 17.0 (CH3) 17.1 (CH3) 
7 35.2 (CH2) 35.2 (CH2) 35.2 (CH2) 35.4 (CH2) 1' 107.0 (CH) 107.0 (CH) 104.8 (CH) 104.9 (CH) 
8 40.0 (C) 40.0 (C) 40.2 (C) 39.8 (C) 2' 75.8 (CH) 75.8 (CH) 83.0 (CH) 83.0 (CH) 
9 50.4 (CH) 50.5 (CH) 48.2 (CH) 50.9 (CH) 3' 78.8 (CH) 78.8 (CH) 78.7 (CH) 78.7 (CH) 
10 37.0 (CH) 37.0 (CH) 37.0 (CH) 37.1 (CH) 4' 71.0 (CH) 71.0 (CH) 71.1 (CH) 71.2 (CH) 
11 32.3 (CH2) 32.1 (CH2) 32.6 (CH2) 32.3 (CH2) 5' 78.4 (CH) 78.4 (CH) 78.3 (CH) 78.4 (CH) 
12 71.9 (CH) 71.9 (CH) 72.4 (CH) 72.6 (CH) 6' 63.1 (CH2) 63.1 (CH2) 63.0 (CH2) 63.0 (CH2) 
13 48.6 (CH) 48.6 (CH) 52.8 (CH) 50.8 (CH) 1''   103.2 (CH) 103.2 (CH) 
14 51.8 (C) 51.8 (C) 51.2 (C) 50.5 (C) 2''   84.6 (CH) 84.6 (CH) 
15 32.3 (CH2) 31.5 (CH2) 32.6 (CH2) 32.7 (CH2) 3''   78.0 (CH) 78.0 (CH) 
16 26.9 (CH2) 26.8 (CH2) 30.9 (CH2) 26.8 (CH2) 4''   71.7 (CH) 71.8 (CH) 
17 54.9 (CH) 54.6 (CH) 50.8 (CH) 51.0 (CH) 5''   77.9 (CH) 77.9 (CH) 
18 16.4 (CH3) 16.4 (CH3) 16.5 (CH3) 16.5 (CH3) 6''   62.8 (CH2) 62.8 (CH2) 
19 16.8 (CH3) 16.8 (CH3) 15.8 (CH3) 16.7 (CH3) 1'''   106.5 (CH) 106.5 (CH) 
20 73.1 (C) 73.3 (C) 155.5 (C) 140.2 (C) 2'''   76.0 (CH) 76.0 (CH) 
21 27.5 (CH3) 27.5 (CH3) 108.0 (CH2) 13.2 (CH3) 3''' 77.8 (CH) 77.9 (CH)
22 31.4 (CH2) 27.0 (CH2) 33.8 (CH2) 123.6 (CH) 4'''   70.7 (CH) 70.8 (CH) 
23 30.7 (CH2) 33.9 (CH2) 27.1 (CH2) 27.5 (CH2) 5''' 67.5 (CH2) 67.5 (CH2)
24 76.1 (CH) 80.1 (CH) 125.4 (CH) 123.8 (CH)      
aRecorded at 100 MHz. 
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are given on a ppm scale with tetramethylsilane as internal 
standard. The MS data were recorded on a VG Auto  
Spec-3000 spectrometer (VG, Manchester, U.K.) with glycerol 
as the matrix. HRESIMS were recorded on an API Qstar Pulsa 
LC/TOF spectrometer. GC analysis was run on a Shimadzu 
GC-14C gas chromatograph. 
Column chromatography was performed with Diaion 101 
resin (Tianjin Haiguang  Chemical Co., Ltd. Tianjin, China), 
silica gel (200–300 mesh, Qingdao Makall Group Co., Ltd. 
Qingdao, China), MCI gel CHP 20P (Mitsubishi Chemical Co. 
Tokyo, Japan), Rp-8 gel, Rp-18 gel (40–60 µm, Merck, Darm-
stadt, Germany) and a 250 × 9.4 mm, i.d., 5µm Zorbax SB-C18 
column (Agilent, California, USA). Thin-layer chromatog-
raphy (TLC) was carried out on silica gel H-precoated plates 
(Qingdao Makall Group Co., Ltd.) with CHCl3/MeOH/H2O 
(8.5:1.5:0.1, 8:2:0.2 or 7:3:0.5, v/v), RP-8 and RP-18 precoated
plates (Merck) with MeOH/H2O (7:3 or 8:2, v/v). Spots were 
detected by spraying with 10% H2SO4 in EtOH followed by 
heating. 
 
Plant Material. Air-dried leaves of P. notoginseng were 
collected from Wenshan County, Yunnan province, China, in 
May, 2008. The raw leaves were mixed with appropriate 
amount of water and steamed at 120oC for 12 h, to give 
steamed leaves. 
 
Extraction and Isolation. The steamed leaves of P.  
notoginseng (10 kg) were extracted with ethanol for three 
times (1.5 h × 3) under reflux. The ethanolic extract was  
concentrated under reduced pressure to small volume, and then 
defatted with petroleum ether for 5 times. After removal of the 
organic solvent, the defatted ethanolic extract was subjected to 
a Diaion 101 resin column, eluting with H2O and EtOH,  
successively. The EtOH elutes were combined and  
concentratedunder reduced pressure to give the total saponin 
fraction (850 g), 200 g of which was subjected to silica gel 
column chromatography (CC) (55 × 6.2 cm) eluted with 
CHCl3/MeOH (95:5, v/v) and CHCl3/MeOH/H2O (9:1:0.1 to 
5:5:1, v/v) to afford 6 fractions (Fr. 1–6). Fr. 1 (12 g) was 
chromatographed over silica gel (CHCl3/MeOH, 95:5 and 
90:10, v/v), Rp-8 gel (MeOH/H2O, 6:4-9:1, v/v), and MCI gel 
CHP 20P (MeOH/H2O, 7:3–1:0, v/v) to afford 20(R/S)-
protopanaxtriol (138 mg). Fr. 2 (25 g) was subjected to  
column chromatography on silica gel (CHCl3/MeOH/H2O, 
95:5:0, 9:1:0.1, 8.5:1.5:0.1 and 8:2:0.2, v/v), Rp-8 gel 
(MeOH/H2O, 6:4–9:1, v/v), and pre-HPLC (MeOH/H2O, 
89:11, v/v) to give ginsenoside R10 (12 mg), Rk2 (11 mg), Rh3 
(7 mg) and Rh2 (1.1 g). In a similar way, compounds 1 (140 
mg), 2 (11 mg), 3 (9 mg), 4 (15 mg), Rk1 (4 mg), Rg5 (9 mg), 
Rs5 (8 mg), Rs4 (6 mg), Rg3 (206 mg), Rs3 (42 mg), Ft1 (51 mg) 
and F2 (8 mg) were obtained from Fr. 3 (31 g) and Fr. 4 (11 g), 
respectively. Each 1 gram sample of Fr. 5 (41 g) and Fr. 6 (36 
g), respectively, was separated by Chromatorex ODS 
(H2O/MeOH 1:1, v/v), silica gel (CHCl3/MeOH/H2O 8:2:0.2–
7:3:0.5) and Rp-8 gel (MeOH/H2O, 6:4–9:1, v/v) to obtain the 
known compounds, gypenoside IX (450 mg), and ginsenosides 
Rb3 (52 mg), Rc (48 mg) and Fc (158 mg). 
 
Notoginsenoside SFt1 (1): white amorphous powder; [α]24D   
+9.4 (c 0.20, MeOH); IR (KBr) νmax 3442, 2947, 1640, 1078, 
1022 cm−1; 1H and 13C NMR data see Tables 1 and 2; FABMS 
m/z 637 [M − H]−, 475 [M – 162 (glucosyl) − H]−; HRESIMS 
m/z 673.4067 [M + Cl]− (calcd. for C36H62O9Cl, 673.4082). 
 
Notoginsenoside SFt2 (2): white amorphous powder; [α]24D   
−3.1 (c 0.12, MeOH); IR (KBr) νmax 3425, 2946, 1640, 1078, 
1021 cm−1; 1H and 13C NMR data see Tables 1 and 2; FABMS 
m/z 656 [M − H]−, 493 [M – 162 (glucosyl) − H]−; HRESIMS 
m/z 691.4150 [M + Cl]− (calcd. for C36H64O10Cl, 691.4188). 
 
Notoginsenoside SFt3 (3): white amorphous powder; [α]24D   
−3.6 (c 0.28, MeOH); IR (KBr) νmax 3424, 2943, 1639, 1076, 
1044 cm−1; 1H and 13C NMR data see Tables 1 and 2; FABMS 
m/z 897 [M − H]−, 765 [M – 132 (xyl) – H]–, 603 [M – 132 
(xyl) – 162 (glucosyl) – H]–; HRESIMS m/z 897.5215 [M – 
H]– (calcd. for C47H77O16, 897.5211). 
 
Notoginsenoside SFt4 (4): white amorphous powder; [α]24D   
−7.2 (c 0.12, MeOH); IR (KBr) νmax 3443, 2927, 1640, 1076, 
1044 cm−1; 1H and 13C NMR data see Tables 1 and 2; FABMS 
m/z 897 [M − H]−, 765 [M − 132 (xyl) − H]−, 603 [M − 132 
(xyl) − 162 (glucosyl) − H]−; HRESIMS m/z 897.5235 [M − 
H]− (calcd. for C47H77O16, 897.5211). 
 
Acidic Hydrolysis of Compounds 1–4. Compounds 1–4 
(each 3–5 mg) were hydrolyzed with 2 M HCl/dioxane (1:1, 4 
mL) under reflux for 6 h, respectively. The reaction mixture 
was extracted with CHCl3 for five times (2 mL × 5). The 
aqueous layer was neutralized with 2 M NaOH and then dried 
to give a monosaccharide mixture. After that, a solution of the 
sugar mixture in pyridine (2 mL) was added to L-cysteine 
methyl ester hydrochloride (about 1.5 mg) and kept at 60°C 
for 1 h. Then trimethylsilylimidazole (about 1.5 mL) was add-
ed to the reaction mixture in ice-water base and kept at 60°C 
for 30 min. The mixture was subjected to GC analysis, run on 
a Shimadzu GC-14C gas chromatograph equipped with a 30 m 
× 0.32 mm i.d. 30QC2/AC-5 quartz capillary column and an 
H2 flame ionization detector with the following conditions: 
column temperature, 180–280°C; programmed increase, 
3 °C/min; carrier gas, N2 (1 mL/min); injector and detector 
temperature, 250°C; injection volume, 4 μL; and split ratio, 
1/50. The configuration of the sugar moiety was determined 
by comparing the retention time with the derivatives of the 
authentic samples. 
 
Cytotoxic Bioassay. Human myeloid leukemia HL-60, 
hepatocellular carcinoma SMMC-7721, lung cancer A-549, 
breast cancer MCF-7, and colon cancer SW480 cell lines were 
used in the cytotoxic assay. The assay was performed by 
means of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenly-
tetrezolium bromide] (Sigma, St. Louis, USA) method19 in 96-
well microplates. All the cells were cultured in RMPI1640 or 
DMEM medium (Hyclone, USA), supplemented with 10% 
fetal bovine serum (Hyclone, USA) in 5% CO2 at 37 °C. 100 μL suspension was added to each well to seed cells in 96-well 
microplates, in which the tested samples were added with  
varied concentrations. After 48 hours incubation, MTT  
solution [5 mg/mL in phosphate buffered saline (PBS)] was 
added (20 μL/well), and the incubation continued for another 
4h to give the formazan product. In each well 100 μL 20% 
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SDS was added after 100 μL medium was removed, and it was 
then incubated over night to make the formazan product  
dissolve completely. The absorbance of the solution was 
measured at 595 nm in Bio-Rad 680. Concentration of a  
compound inhibiting 50% of cell growth (IC50) was calculated 
by the Reed and Muench method. 
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